본문으로 건너뛰기
← 뒤로

PSMA-negative Widespread Metastases Identified by 18 F-FDG PET/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation.

1/5 보강
Clinical nuclear medicine 📖 저널 OA 3.4% 2021: 0/2 OA 2022: 1/12 OA 2023: 0/8 OA 2024: 0/22 OA 2025: 3/79 OA 2026: 4/104 OA 2021~2026 2026 Vol.51(1) p. 70-72
Retraction 확인
출처

Li Y, Gao X, Yang J, Tang Y, Hu S

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

A 62-year-old man had prostate cancer treated for 5 years with prostatectomy, radiation, and hormonal therapy.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Li Y, Gao X, et al. (2026). PSMA-negative Widespread Metastases Identified by 18 F-FDG PET/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation.. Clinical nuclear medicine, 51(1), 70-72. https://doi.org/10.1097/RLU.0000000000006106
MLA Li Y, et al.. "PSMA-negative Widespread Metastases Identified by 18 F-FDG PET/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation.." Clinical nuclear medicine, vol. 51, no. 1, 2026, pp. 70-72.
PMID 40804770 ↗

Abstract

A 62-year-old man had prostate cancer treated for 5 years with prostatectomy, radiation, and hormonal therapy. He presented with worsening back pain for 3 months. Serum prostate-specific antigen was very low (<1.0 ng/mL), while neuron-specific enolase was elevated (23.35 ng/mL), raising suspicion of neuroendocrine differentiation. Dual-tracer PET/CT was performed. 68 Ga-PSMA PET/CT showed no recurrence or metastasis, while 18 F-FDG PET/CT revealed widespread hypermetabolic bone lesions and retrocrural nodal disease. Biopsy confirmed treatment-related neuroendocrine prostate cancer with squamous differentiation. This rare phenotype exhibited typical PSMA-negativity and intense FDG uptake. It emphasizes the diagnostic potential of 18 F-FDG PET/CT in dedifferentiated prostate cancers.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반